Senolytics: Clearing Zombie Cells to Slow Aging

The Zombie Cell Problem

Cellular senescence is a state in which a cell permanently stops dividing but does not die. Instead, it lingers in tissues, secreting inflammatory cytokines — the senescence-associated secretory phenotype (SASP). As we age, senescent cells accumulate and drive chronic inflammation, tissue dysfunction, and age-related disease.

The Leading Senolytic Compounds

Dasatinib + Quercetin (D+Q)

The original senolytic combination. The first human pilot trial (2019, The Lancet eBioMedicine) demonstrated decreased senescent cells and improved physical function in diabetic kidney disease patients after just three days.

Fisetin

In mice, fisetin increased average healthy lifespan by approximately 20%. The AFFIRM trial evaluates fisetin in older adults with frailty.

Next-Generation Approaches

Senolytic CAR-T cells, senolytic vaccines, antibody-drug conjugates, and PROTAC-based senolytics are in development.

The Hit-and-Run Dosing Principle

Senolytics work on intermittent dosing — 1-3 days followed by weeks of rest — because once a senescent cell is eliminated, it does not regrow.

Important Caveats

No senolytic has been approved for anti-aging use. Long-term safety data is lacking. Senescent cells are not purely harmful — they aid wound healing and immune surveillance.

---

At Genoryx, we monitor senescence-associated biomarkers as part of our comprehensive panels. Book a consultation and navigate the science with precision and honesty.